Promontory Therapeutics names new chief financial officer
29 November 2022 -

Promontory Therapeutics Inc., a New York-based clinical stage pharmaceutical company, announced on Monday that it has named Stanley J Musial, CPA, MBA, as its new chief financial officer.

Musial has more than 25 years of financial, strategic and managerial experience with public and private biotechnology companies. He has earlier served as CFO of Aruvant Sciences, CFO and chief business officer of Xenikos BV, CFO of Erydel SpA, executive vice president and CFO at Egalet, CFO and financial positions at several other biotechnology, medical device and healthcare services companies. He started his career at the public accounting firm KPMG.

Musial has an MBA degree from Temple University, a BS degree in Accounting from Pennsylvania State University, and is a certified public accountant.